Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Pick Your Number one Sort Of Music - 2I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- 3Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- 4Instructions to Decide the Best SUV Size for Seniors
- 5Southern Californians, your health insurance costs could rise in 2026
- Vote In favor of Your Favored Web-based Book Retailor
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- Merck sees over $5 billion opportunity in Cidara's experimental flu drug
- The Best Cell phone Brands for Tech Aficionados
- Opening Potential: Self-awareness and Long lasting Learning
- This cafe takes orders in sign language. It's cherished by the Deaf community
- Step by step instructions to Analyze Senior Insurance Contracts Really.
